Glenmark to pay USD 7 mn to settle lawsuits with three entities in U.S.

Glenmark Pharmaceuticals settles U.S. lawsuits for $7 million related to generic drugs, denying all allegations.

Glenmark Pharmaceuticals on Monday (February 24, 2025) said it will pay USD 7 million to three entities to settle lawsuits in the U.S. related to generic drugs.

In a regulatory filing, the Mumbai-based drug maker said that in 2023 it had settled with three plaintiff groups referred as the Direct Purchaser Plaintiffs, the Retailer Plaintiffs, and the End-Payor Plaintiffs.

Four End-Payor Plaintiffs, Humana Inc, Centene, Kaiser Foundation Health Plan, Inc, and United Healthcare Services, Inc opted out of the 2023 settlements, it said.

The four lawsuits, which included claims related to both generic Zetia and Vytorin, were subsequently remanded to the jurisdictions in which they were originally filed.

"With a view to resolve this dispute and avoid uncertainty, Glenmark has agreed to enter into a settlement with three plaintiffs, Humana, Centene and Kaiser, for a total of USD 7 million," the drug firm said.

The settlement makes clear that Glenmark denies each and every one of the allegations against it and the settlement is not on the basis of the drugmaker having conceded or admitted any liability or illegality, it added.

Glenmark said it along with subsidiary GlenmarkPharmaceuticals Inc, USA faced multiple antitrust and consumer protection lawsuits, including a class action, consolidated in the Eastern District of Virginia, U.S. in connection with generic Zetia, a drug for the treatment of cholesterol.